[
  {
    "id": 1072,
    "name": "Silver",
    "slug": "silver",
    "former_names": [],
    "small_logo_thumb_url": "/company/thumb/missing.png",
    "website": "http://www.scansilver.com/",
    "all_locations": "Cupertino, CA, USA",
    "long_description": "At Silver, they are building the world's first miniaturized Raman spectroscope for consumers. Our spectroscope, combined with our proprietary nanoparticle substrates, enables our users to detect many contaminants instantaneously.",
    "one_liner": "Low cost consumer device for toxin detection. ",
    "team_size": 0,
    "industry": "Consumer",
    "subindustry": "Consumer -> Consumer Electronics",
    "launched_at": 1447748416,
    "tags": [
      "Hard Tech",
      "Diagnostics",
      "Nanotechnology"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Winter 2016",
    "status": "Inactive",
    "industries": [
      "Consumer",
      "Consumer Electronics"
    ],
    "regions": [
      "United States of America",
      "America / Canada"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/silver",
    "api": "https://yc-oss.github.io/api/batches/winter-2016/silver.json"
  },
  {
    "id": 1235,
    "name": "Shield Bio",
    "slug": "shield-bio",
    "former_names": [
      "TL Biolabs",
      "Shield Diagnostics"
    ],
    "small_logo_thumb_url": "/company/thumb/missing.png",
    "website": "http://shieldbio.com",
    "all_locations": "San Jose, CA, USA",
    "long_description": "Shield Bio is a precision medicine company with a\r\nproprietary platform that enables reliable nanopore\r\nsequencing in under a minute, in a clinical setting. It is\r\nfocused on bringing 3rd generation or \"nanopore\"\r\nsequencing into clinical use to deliver on the promise of\r\nprecision medicine. Shield is initially using the technology to\r\nimprove the treatment of infectious disease and address the\r\nunmet clinical need of sepsis, which kills 300,000 people a\r\nyear in the US alone.",
    "one_liner": "Bringing 3rd generation, nanopore sequencing to healthcare to solve…",
    "team_size": 28,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Diagnostics",
    "launched_at": 1461210620,
    "tags": [
      "Healthcare",
      "Genomics",
      "Nanotechnology"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Summer 2016",
    "status": "Inactive",
    "industries": [
      "Healthcare",
      "Diagnostics"
    ],
    "regions": [
      "United States of America",
      "America / Canada"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/shield-bio",
    "api": "https://yc-oss.github.io/api/batches/summer-2016/shield-bio.json"
  },
  {
    "id": 1504,
    "name": "Arylla",
    "slug": "arylla",
    "former_names": [
      "Arylla Inc."
    ],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/625cc8316448d38d73101072829a6b5898adf51f.png",
    "website": "http://www.arylla.com",
    "all_locations": "Kitchener, ON, Canada",
    "long_description": "Arylla has created a printable tag that can be scanned with any phone using our API. We piggyback on legacy commercial printers to get our tag onto products at scale and license our API to developers who build services on top of our tag. We are 10x less expensive and much more scalable than alternatives like NFC.",
    "one_liner": "We connect products to the internet using an invisible, chip-less tag",
    "team_size": 6,
    "industry": "Industrials",
    "subindustry": "Industrials -> Manufacturing and Robotics",
    "launched_at": 1478577033,
    "tags": [
      "IoT",
      "Nanotechnology"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Winter 2017",
    "status": "Inactive",
    "industries": [
      "Industrials",
      "Manufacturing and Robotics"
    ],
    "regions": [
      "Canada",
      "America / Canada",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/arylla",
    "api": "https://yc-oss.github.io/api/batches/winter-2017/arylla.json"
  },
  {
    "id": 1560,
    "name": "Helix Nanotechnologies",
    "slug": "helix-nanotechnologies",
    "former_names": [
      "Helix Nanotechnologies"
    ],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f05a634de42c2c96484608b63b33b99fd27aa56e.png",
    "website": "http://helixnano.com",
    "all_locations": "Boston, MA, USA; Cambridge, MA, USA",
    "long_description": "Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button.\r\n\r\nBy focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity.\r\n\r\nRigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas.\r\n\r\nWe've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.",
    "one_liner": "Next-generation mRNA platform to solve cancer, COVID and climate.",
    "team_size": 22,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Drug Discovery and Delivery",
    "launched_at": 1482443417,
    "tags": [
      "Artificial Intelligence",
      "Biotech",
      "Genomics",
      "Nanotechnology"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Winter 2017",
    "status": "Active",
    "industries": [
      "Healthcare",
      "Drug Discovery and Delivery"
    ],
    "regions": [
      "United States of America",
      "America / Canada",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Growth",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/helix-nanotechnologies",
    "api": "https://yc-oss.github.io/api/batches/winter-2017/helix-nanotechnologies.json"
  },
  {
    "id": 12664,
    "name": "Kern Systems",
    "slug": "kern-systems",
    "former_names": [],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/960f475f7529b916c176fbf83565873d60242a91.png",
    "website": "https://www.kernsystems.com",
    "all_locations": "Boston, MA, USA",
    "long_description": "DNA has emerged as a compelling data storage medium due to its density, longevity, and eternal relevance compared to current memory technologies. However, the high price of synthesizing DNA remains a major bottleneck for adoption of this promising storage solution. We are pioneering new approaches to synthesizing DNA for data storage with enzymes and custom digital codecs. We are building an interdisciplinary team to build the world's most scalable information infrastructure in DNA. \r\n\r\nWe seek technical experts in enzyme engineering, chemistry, hardware engineering, and information theory. We also seek business development to identify emerging markets for early use cases of our technology.",
    "one_liner": "Using DNA to store data.",
    "team_size": 3,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Industrial Bio",
    "launched_at": 1556764621,
    "tags": [
      "Genomics",
      "Nanotechnology"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Summer 2019",
    "status": "Active",
    "industries": [
      "Healthcare",
      "Industrial Bio"
    ],
    "regions": [
      "United States of America",
      "America / Canada"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/kern-systems",
    "api": "https://yc-oss.github.io/api/batches/summer-2019/kern-systems.json"
  },
  {
    "id": 12666,
    "name": "spotLESS Materials",
    "slug": "spotless-materials",
    "former_names": [],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f4bcbe21be5fc35568846a259c348e3973168839.png",
    "website": "https://www.industry.spotlessmaterials.com",
    "all_locations": "State College, PA, USA",
    "long_description": "Surface fouling is a costly challenge across industries, impacting medical consumables, diagnostic devices, and automotive components. Contamination from substances like mud, ice, and sludge can compromise performance and lead to frequent cleaning, repairs, and replacements.\r\n\r\nOur PFAS-free coating, which we first launched as a consumer product, has quickly expanded into industrial partnerships. It dramatically reduces contamination on critical surfaces such as glass, metal, ceramic, and now plastics too. Whether for medical devices or automotive components, our coating protects against surface fouling\r\nCurrently our coatings work best on glass, metal, and ceramic surfaces. ",
    "one_liner": "Repellent coatings without PFAS",
    "team_size": 6,
    "industry": "Industrials",
    "subindustry": "Industrials",
    "launched_at": 1556766727,
    "tags": [
      "Hard Tech",
      "Nanotechnology",
      "Advanced Materials"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Summer 2019",
    "status": "Active",
    "industries": [
      "Industrials"
    ],
    "regions": [
      "United States of America",
      "America / Canada",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/spotless-materials",
    "api": "https://yc-oss.github.io/api/batches/summer-2019/spotless-materials.json"
  },
  {
    "id": 13506,
    "name": "Nomic Bio",
    "slug": "nomic-bio",
    "former_names": [
      "nplex biosciences"
    ],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d3005075624cbc032b9abdd1525e6ec3201158f5.png",
    "website": "http://www.nomic.bio",
    "all_locations": "Montreal, QC, Canada",
    "long_description": "Nomic is doing for protein profiling, what Illumina did for DNA sequencing. Our core technology, the nELISA, is a next-gen immunoassay platform that transforms the ELISA into a high-throughput, high-content, and high-versatility tool. \r\n\r\nToday we developed the nELISA for high-throughput drug discovery scientists, enabling them profile 100s of proteins at 10x higher throughput and 10x lower cost compared to existing solutions. We're offering the nELISA through early access programs to HTS groups in top pharmas as well as pioneering biotechs in the space.\r\n\r\nOur goal is to create a ubiquitous technology that consolidates the broad range of legacy immunoassay toolkits that scientists use today with a single platform that can carry the science end-to-end, from discovery all the way to the clinic. \r\n\r\nWe're a team of engineers, biologists, and highly-skilled lab operators that are looking to grow quickly to keep up with customer demand but also to continue developing our core technology, scale our multiplexing/throughput, and build our software stack. We're hiring on a number of positions including engineering, software, biology, and ops. Come talk to us!",
    "one_liner": "Nomic is doing for proteins what Illumina has done for DNA",
    "team_size": 24,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Diagnostics",
    "launched_at": 1583898031,
    "tags": [
      "Nanotechnology"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": true,
    "nonprofit": false,
    "batch": "Winter 2020",
    "status": "Active",
    "industries": [
      "Healthcare",
      "Diagnostics"
    ],
    "regions": [
      "Canada",
      "America / Canada",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Growth",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/nomic-bio",
    "api": "https://yc-oss.github.io/api/batches/winter-2020/nomic-bio.json"
  },
  {
    "id": 25151,
    "name": "Keylika",
    "slug": "keylika",
    "former_names": [],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/bd12fc4dc5d053441f31a9c528579e0d16f3449e.png",
    "website": "https://www.keylika.com",
    "all_locations": "Walnut Creek, CA, USA",
    "long_description": "Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. \r\n\r\nOur first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.",
    "one_liner": "Redefining the Standard of Care for Iron Deficiency Anemia",
    "team_size": 1,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Therapeutics",
    "launched_at": 1658519436,
    "tags": [
      "AI-powered Drug Discovery",
      "Medical Devices",
      "Drug Delivery",
      "Nanotechnology",
      "Therapeutics"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Summer 2022",
    "status": "Active",
    "industries": [
      "Healthcare",
      "Therapeutics"
    ],
    "regions": [
      "United States of America",
      "America / Canada",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": true,
    "app_answers": true,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/keylika",
    "api": "https://yc-oss.github.io/api/batches/summer-2022/keylika.json"
  },
  {
    "id": 28112,
    "name": "Persist AI",
    "slug": "persist-ai",
    "former_names": [
      "Persist AI",
      "Persist AI Formulations Corp"
    ],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/eeb1e38a6ca6e6061c101deae73f22c28c142596.png",
    "website": "http://www.persist-ai.com",
    "all_locations": "Woodland, CA, USA",
    "long_description": "It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.",
    "one_liner": "Developing long-lasting drug formulations 50% faster",
    "team_size": 6,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Drug Discovery and Delivery",
    "launched_at": 1671420729,
    "tags": [
      "Machine Learning",
      "Robotics",
      "Microfluidics",
      "Nanotechnology",
      "Therapeutics"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Winter 2023",
    "status": "Active",
    "industries": [
      "Healthcare",
      "Drug Discovery and Delivery"
    ],
    "regions": [
      "United States of America",
      "America / Canada",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Growth",
    "app_video_public": true,
    "demo_day_video_public": true,
    "app_answers": true,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/persist-ai",
    "api": "https://yc-oss.github.io/api/batches/winter-2023/persist-ai.json"
  },
  {
    "id": 28159,
    "name": "Invitris",
    "slug": "invitris",
    "former_names": [],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b31c6e14e61e0a7e292383c88d7094914a492565.png",
    "website": "https://invitris.com/",
    "all_locations": "Munich, BY, Germany",
    "long_description": "Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.\r\n\r\nOur killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined. ",
    "one_liner": "Creating new protein-based drugs at scale",
    "team_size": 6,
    "industry": "Healthcare",
    "subindustry": "Healthcare -> Drug Discovery and Delivery",
    "launched_at": 1678475135,
    "tags": [
      "Biotech",
      "Nanotechnology",
      "Drug discovery"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Winter 2023",
    "status": "Active",
    "industries": [
      "Healthcare",
      "Drug Discovery and Delivery"
    ],
    "regions": [
      "Germany",
      "Europe",
      "Remote",
      "Partly Remote"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/invitris",
    "api": "https://yc-oss.github.io/api/batches/winter-2023/invitris.json"
  },
  {
    "id": 30466,
    "name": "Labric",
    "slug": "labric",
    "former_names": [],
    "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2d2328f04b2a69a293a3f3a79d7e648159242574.png",
    "website": "https://labric.co",
    "all_locations": "San Francisco, CA, USA",
    "long_description": "Labric is building the data layer that makes AI work for science. We capture messy lab data from instruments and tools, clean it, and connect it— so researchers can actually use AI to accelerate discovery.",
    "one_liner": "The data layer for scientific research",
    "team_size": 2,
    "industry": "B2B",
    "subindustry": "B2B -> Analytics",
    "launched_at": 1747086610,
    "tags": [
      "Biotech",
      "Nanotechnology",
      "Data Engineering",
      "Advanced Materials",
      "AI"
    ],
    "tags_highlighted": [],
    "top_company": false,
    "isHiring": false,
    "nonprofit": false,
    "batch": "Spring 2025",
    "status": "Active",
    "industries": [
      "B2B",
      "Analytics"
    ],
    "regions": [
      "United States of America",
      "America / Canada"
    ],
    "stage": "Early",
    "app_video_public": false,
    "demo_day_video_public": false,
    "app_answers": null,
    "question_answers": false,
    "url": "https://www.ycombinator.com/companies/labric",
    "api": "https://yc-oss.github.io/api/batches/spring-2025/labric.json"
  }
]
